All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
On January 5, 2021, the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on a phase II trial (NCT04511130) evaluating MT-401 for patients with acute myeloid leukemia (AML) following allogeneic transplant.
MT-401 is a multi-tumor-associated antigen (MultiTAA)-specific T-cell product able to target a broad range of tumor antigens simultaneously. In April 2020, the product received FDA orphan drug designation in the posttransplant AML setting.
The phase II multicenter trial was designed to determine the safety and efficacy of MT-401 in both the adjuvant and active disease settings. Approximately 120 patients enrolled in the adjuvant group will be randomized 1:1 to receive either MT-401 90 days posttransplant or standard-of-care observation. In the single-arm, active disease group, around 40 patients will receive MT-401. Primary endpoints include relapse-free survival in the adjuvant group, as well as complete remission rates and duration of complete remission in patients with active AML. Further objectives include the following:
This decision will allow the continued enrollment of patients in the second part of the safety lead-in portion and subsequent studies.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content